 Home > Active Ingredient News > Antitumor Therapy > AstraZeneia's Imfinzi failed to improve the overall survival rate of patients with head and neck cancer

AstraZeneia's Imfinzi failed to improve the overall survival rate of patients with head and neck cancer

 Last Update: 2021-02-24
 Source: Internet
 Author: User

Tags

treatment high ferritin levels

phase glass needles

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the second trial, AstraZeneca's Imfinzi failed to improve the overall survival of patients with relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) (OS).
update to Imfinzi's KESTREL PHASE III clinical trial found that in HNSCC patients with high levels of PD-L1, Imfinzi (durvalumab) did not improve OS compared to chemotherapy-combined sytoxidotherapy.
combination of Imfinzi and CTLA-4 targeted antibody tremelimumab also failed to improve OS in patients.
, executive vice president of AstraZeneta's Oncology business unit, said: "Metastatic head and neck cancer is a complex and challenging disease with poor prognostics.
while we are disappointed with these results, the experience from the KESTREL Phase III trial will enhance our understanding of immunotherapy."
, Imfinzi also failed to show benefits in HNSCC patients in the 2018 EAGLE Phase III trial.
EAGLE Phase III trial evaluated patients with relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) progression after treatment with platinum chemotherapy with Imfinzi monotherapy or Imfinzi combined tremelimumab, and showed that imfinzi monotherapy and imfinzi combined treatment withtreimumab did not improve OS compared to standard chemotherapy (SoC) regardless of patient PD-L1 levels.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.